literature

HBV mutation literature information.

Pre-existing mutations related to tenofovir in chronic hepatitis B patients with long-term nucleos(t)ide analogue drugs treatment by ultra-deep pyrosequencing.

PMID: 27602500 2016 Oncotarget

Result: Other substitutions (rtI169T/V, rtP177G, rtT184A/I, rtA194V/T, rtV214A, rtQ215R/H, rtF249A, and rtM250V) were present at low levels (<1%).

Dynamics of Genotypic Mutations of the Hepatitis B Virus Associated With Long-Term Entecavir Treatment Determined With Ultradeep Pyrosequencing: A Retrospective Observational Study.

PMID: 26825915 2016 Medicine

Result: Other substitutions (rtI169T/V, rtV173A/M, rtT184A/I, rtA194 V/T, rtQ215R/H, rt

Result: Other substitutions (rtI169T/V, rtT184A/I, rtA194 V/T, rtV214A, rtM250 V) were present at low levels (<1%).

Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial.

PMID: 25596179 2016 Gut

Abstract: All patients had at least one ETV-resistance mutation: rtT184A/C/F/G/I/L/S (n=49), rtS202G (n=43) and rtM250L/V (n=7), in addition to rtM204V/I (n=90).

Epidemiology study of HBV genotypes and antiviral drug resistance in multi-ethnic regions from Western China.

PMID: 26612031 2015 Scientific reports

Introduction: Combination of rtM204V/I, rtL180M plus one of the following mutations: rtT184S/C/I/A, rtS202G/C/I or rtM250V links to ETV resistance.

Result: Nevertheless, LMV-associated mutation rtM204V/I and rtL180M, LdT-associated mutation rtM204I, and ETV-associated mutations rtT184A/I/S,

Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir.

PMID: 25061278 2014 Drug design, development and therapy

Abstract: At the start of combination therapy, amino acid substitutions of the reverse transcriptase (rt) gene, rtL180M, rtT184I/M, and rtM204V, were detected.

Conclusion: In June 2010 (week 3 of ETV retreatment), amino acid substitutions of rtL180M, rt

Discussion: Moreover, Karatayli et al reported that HBV DNA, in seven of eight patients with ETV resistance mutations (T184F/A/L/I, S202G, and M250V), became undetectable with TDF and LAM after 6 months of treatment.

Adefovir and lamivudine combination therapy in patients with entecavir-resistant chronic hepatitis B: antiviral responses and evolution of mutations.

PMID: 24993731 2014 Intervirology

Abstract: The rtT184L/I/A/F (50%), rtS202G (25%) and mixed ETV-resistant mutations (25%) were detected at enrollment.

Novel natural mutations in the hepatitis B virus reverse transcriptase domain associated with hepatocellular carcinoma.

PMID: 24788140 2014 PloS one

Result: It is worth noting that we did not observe any of the common NA-related resistance mutations including rtM204V/I, rtS202C/G/I, rtL180M, rtA181T/V, rtT184A/I/L/G/C/M, rtA194T, rtI169T, rtV173L, rtL80I, rtN236T, and

PMID: 24586482 2014 PloS one

Result: The rtM204Q emerged either alone or in concomitance with other mutations (rtM204I/V, rtA181T, rtL180M, rtT184I) by direct sequencing.

Table: T184I

Clonal analysis of the quasispecies of antiviral-resistant HBV genomes in patients with entecavir resistance during rescue treatment and successful treatment of entecavir resistance with tenofovir.

PMID: 22878399 2013 Antiviral therapy

Abstract: All clones had >=1 of the S202G, T184F, T184A, T184L, T184I and M250V ETV resistance mutations.

Effects of antiviral therapy on the recurrence of hepatocellular carcinoma after curative resection or liver transplantation.

PMID: 23166535 2012 Hepatitis monthly

Introduction: However, in the presence of rtM204I/V mutations, ETV resistance arose with the coexistence of rtI169T, rtL180M, rtT184A/F/G/I/L/S, rtS202G/I, or rtM250V mutations.

Browser Board

Co-occurred Entities

Filtrator